9 Meters Biopharma, Inc. (NMTR): Price and Financial Metrics
GET POWR RATINGS... FREE!
NMTR Stock Price Chart Interactive Chart >
NMTR Price/Volume Stats
|Current price||$0.45||52-week high||$1.55|
|Prev. close||$0.48||52-week low||$0.35|
|Day high||$0.49||Avg. volume||1,353,752|
|50-day MA||$0.49||Dividend yield||N/A|
|200-day MA||$0.88||Market Cap||116.05M|
9 Meters Biopharma, Inc. (NMTR) Company Bio
9 Meters Biopharma, Inc. operates as a biotechnological company. The Company focuses on development of drugs and treatments for rare disorders and unmet needs. 9 Meters Biopharma serves customers worldwide.
Most Popular Stories View All
NMTR Latest News Stream
|Loading, please wait...|
NMTR Latest Social Stream
View Full NMTR Social Stream
Latest NMTR News From Around the Web
Below are the latest news stories about 9 Meters Biopharma Inc that investors may wish to consider to help them evaluate NMTR as an investment opportunity.
RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today that John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, Inc.
Investment company Paradigm, Strategies in Wealth Management, LLC (Current Portfolio) buys iShares iBonds Dec 2023 Term Corporate ETF, iShares iBonds Dec 2023 Term Muni Bond ETF, Costco Wholesale Corp, Prologis Inc, Altria Group Inc, sells iShares iBonds Dec 2021 Term Corporate ETF, iShares iBonds Dec 2021 Term Muni Bond ETF, Wells Fargo, Invesco Preferred ETF, Schwab International Equity ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Paradi
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.
A relatively new biopharmaceutical company in Raleigh has added a new name to its C-suite. 9 Meters Biopharma (Nasdaq: NMTR) has appointed Bethany Sensenig to be chief financial officer. Sensenig is joining the clinical-stage company, which is focused on developing drugs for rare digestive diseases, less than two years after it was formed via a three-way merger that involved a Triangle drugmaker.
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer.
NMTR Price Returns